Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Debt (2020 - 2024)

Syndax Pharmaceuticals (SNDX) has 5 years of Total Debt data on record, last reported at $343.7 million in Q4 2024.

  • For Q4 2024, Total Debt changed N/A year-over-year to $343.7 million; the TTM value through Dec 2024 reached $343.7 million, changed N/A, while the annual FY2024 figure was $343.7 million, N/A changed from the prior year.
  • Total Debt reached $343.7 million in Q4 2024 per SNDX's latest filing, up from $20.2 million in the prior quarter.
  • Across five years, Total Debt topped out at $343.7 million in Q4 2024 and bottomed at $19.8 million in Q1 2020.
  • Average Total Debt over 4 years is $49.5 million, with a median of $20.1 million recorded in 2020.
  • Peak YoY movement for Total Debt: rose 2.36% in 2021, then fell 0.92% in 2022.
  • A 4-year view of Total Debt shows it stood at $20.1 million in 2020, then decreased by 0.18% to $20.1 million in 2021, then grew by 0.62% to $20.2 million in 2022, then surged by 1600.89% to $343.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for Total Debt were $343.7 million in Q4 2024, $20.2 million in Q2 2022, and $20.0 million in Q1 2022.